CLAIMS

1. A pharmaceutical composition comprising:

(i) a polypeptide comprising at least one amino acid sequence comprising at least 8 contiguous amino acids of:
FSHSSHMLTTPTPMHPPSSLSFGPHPPLQHGHRHGLEPCSMLTGPPARVPAVPFD LHFCRSSIMKPKRDGYMFLKAESKIMFATLQRSSLWCLCSNH,

(ii) a nucleic acid encoding the polypeptide,

(iii) antigen presenting cells (APCs) comprising (i) or (ii), or

(iv) T cells stimulated with APCs comprising (i) or (ii); and

a pharmaceutically acceptable carrier.

2. A pharmaceutical composition according to Claim 1, in which the at least one amino acid sequence binds to a protein encoded by an HLA allele.

3. A pharmaceutical composition according to Claim 2, in which the at least one amino acid sequence binds to a protein encoded by an HLA-A, HLA-B or HLA-C allele with a K_D of less than 500 nM.

4. A pharmaceutical composition according to Claim 2, in which the at least one amino acid sequence binds to a protein encoded by a class II HLA allele with a binding affinity of less than 1000 nM.

5. A pharmaceutical composition according to Claim 1, in which the polypeptide is from 8 to 50 amino acids in length.

6. A pharmaceutical composition according to Claim 1, in which the at least one amino acid sequence comprises at least 8 amino contiguous acids of:

PPLQHGHRHGLEPCSMLTGPPARVPAVPFDLHFCRSSIMKPKRDGYMFLKAESK IMFATLQRSSLWCLCSNH.

7. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence ESKIMFATL.

8. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence FATLQRSSL.

9. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence FLKAESKIM.

10. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence FLKAESKIMF.

11. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence GPPARVPAV.

12. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence IMKPKRDGYM.

13. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence KIMFATLQR.

14. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence KPKRDGYMF.

15. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence KPKRDGYMFL.

16. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence LHFCRSSIM.

17. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence MFATLQRSSL.

18. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence MFLKAESKI.

19. TA pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence MLTGPPARV.

20. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence QPVLWTTPPL.

21. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence SMLTGPPARV.

22. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence TLQRSSLWCL.

23. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence VLPEPHLAL.

24. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence: YMFLKAESK.

25. A pharmaceutical composition according to Claim 1, in which the polypeptide comprises an amino acid sequence YMFLKAESKI.

26. A pharmaceutical composition according to Claim 1, in which the pharmaceutical composition comprises (iv).

27. A pharmaceutical composition according to Claim 1, in which the pharmaceutical composition comprises (i) or (ii).

28. A pharmaceutical composition according to Claim 1, further comprising an adjuvant or an immunomodulator.

29. A pharmaceutical composition according to Claim 28, in which the immunomodulator or adjuvant is poly(I:C).

30. A pharmaceutical composition according to Claim 1, in which the pharmaceutical composition is an immunogenic composition or a vaccine composition.

31. A polypeptide, nucleic acid, antigen presenting cells (APCs) or T cells according to any of Claims 1 to 30 for use in treating cancer in a subject in need thereof.

32. Use of a polypeptide, nucleic acid, antigen presenting cells (APCs) or T cells according to any of Claims 1 to 30 in the manufacture of a medicament for the treatment of cancer in a subject in need thereof.